z-logo
open-access-imgOpen Access
Mobilization of Stem Cells Using G-CSF for Acute Ischemic Stroke: A Randomized Controlled, Pilot Study
Author(s) -
Kameshwar Prasad,
Amit Kumar,
Jitendra Kumar Sahu,
M. V. Padma Srivastava,
Sujata Mohanty,
Rohit Bhatia,
Shailesh Gaikwad,
Achal Kumar Srivastava,
Vinay Goyal,
Manjari Tripathi,
Chandrashekar Bal,
Nalini Mishra
Publication year - 2011
Publication title -
stroke research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.939
H-Index - 34
eISSN - 2090-8105
pISSN - 2042-0056
DOI - 10.4061/2011/283473
Subject(s) - medicine , modified rankin scale , tolerability , randomized controlled trial , adverse effect , stroke (engine) , physical therapy , barthel index , clinical trial , ischemic stroke , activities of daily living , ischemia , mechanical engineering , engineering
Background . There is emerging evidence to support the use of granulocyte colony-stimulating factor (G-CSF) therapy in patients with acute ischemic stroke. Aims . To explore feasibility, safety, and preliminary efficacy of G-CSF therapy in patients with acute ischemic stroke. Patients and Method . In randomized study, 10 patients with acute ischemic stroke were recruited in 1 : 1 ratio to receive 10  μ g/kg G-CSF treatment subcutaneously daily for five days with conventional care or conventional treatment alone. Efficacy outcome measures were assessed at baseline, one month, and after six months of treatment included Barthel Index (BI), National Institute of Health Stroke Scale, and modified Rankin Scale. Results . One patient in G-CSF therapy arm died due to raised intracranial pressure. No severe adverse effects were seen in rest of patients receiving G-CSF therapy arm or control arm. No statistically significant difference between intervention and control was observed in any of the scores though a trend of higher improvement of BI score is seen in the intervention group. Conclusion . Although this study did not have power to examine efficacy, it provides preliminary evidence of potential safety, feasibility, and tolerability of G-CSF therapy. Further studies need to be done on a large sample to confirm the results.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom